Walter M Gregory
Overview
Explore the profile of Walter M Gregory including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
3350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Cohen D, Todd S, Gregory W, Brown J
Trials
. 2015 Apr;
16:179.
PMID: 25897686
Incorporating an emerging therapy as a new randomisation arm in a clinical trial that is open to recruitment would be desirable to researchers, regulators and patients to ensure that the...
32.
Rawstron A, Gregory W, De Tute R, Davies F, Bell S, Drayson M, et al.
Blood
. 2015 Feb;
125(12):1932-5.
PMID: 25645353
The detection of minimal residual disease (MRD) in myeloma using a 0.01% threshold (10(-4)) after treatment is an independent predictor of progression-free survival (PFS), but not always of overall survival...
33.
Pawlyn C, Melchor L, Murison A, Wardell C, Brioli A, Boyle E, et al.
Blood
. 2014 Nov;
125(5):831-40.
PMID: 25428216
The acquisition of the cytogenetic abnormalities hyperdiploidy or translocations into the immunoglobulin gene loci are considered as initiating events in the pathogenesis of myeloma and were often assumed to be...
34.
Wu P, Walker B, Broyl A, Kaiser M, Johnson D, Kuiper R, et al.
Leuk Lymphoma
. 2014 Jun;
56(3):594-601.
PMID: 24913504
Myeloma is characterized by a highly variable clinical outcome. Despite the effectiveness of high-dose therapy, 15% of patients relapse within 1 year. We show that these cases also have a...
35.
Brioli A, Giles H, Pawlyn C, Campbell J, Kaiser M, Melchor L, et al.
Blood
. 2014 Apr;
123(22):3414-9.
PMID: 24733348
Intraclonal heterogeneity was recently described in multiple myeloma (MM), but its full impact on disease progression and relapse has not been entirely explored. The immunoglobulin type produced by myeloma cells...
36.
Jackson G, Morgan G, Davies F, Wu P, Gregory W, Bell S, et al.
Br J Haematol
. 2014 Mar;
166(1):109-17.
PMID: 24673708
Bisphosphonates are recommended in patients with osteolytic lesions secondary to multiple myeloma. We report on the safety of bisphosphonate therapy with long-term follow-up in the Medical Research Council Myeloma IX...
37.
Viprey V, Gregory W, Corrias M, Tchirkov A, Swerts K, Vicha A, et al.
J Clin Oncol
. 2014 Mar;
32(10):1074-83.
PMID: 24590653
Purpose: To evaluate the hypothesis that detection of neuroblastoma mRNAs by reverse transcriptase quantitative polymerase chain reaction (RTqPCR) in peripheral blood (PB) and bone marrow aspirates (BM) from children with...
38.
Rawstron A, Child J, De Tute R, Davies F, Gregory W, Bell S, et al.
J Clin Oncol
. 2014 Jan;
32(5):476-7.
PMID: 24419132
No abstract available.
39.
Morgan G, Davies F, Gregory W, Bell S, Szubert A, Cook G, et al.
Clin Cancer Res
. 2013 Sep;
19(21):6030-8.
PMID: 23995858
Purpose: Medical Research Council (MRC) Myeloma IX was a phase III trial evaluating bisphosphonate and thalidomide-based therapy for newly diagnosed multiple myeloma. Results were reported previously after a median follow-up...
40.
Larocca A, Child J, Cook G, Jackson G, Russell N, Szubert A, et al.
Blood
. 2013 Aug;
122(17):2974-7.
PMID: 23974194
Significant benefits for zoledronic acid (ZOL) over clodronate acid (CLO) were seen in the Medical Research Council Myeloma IX randomized trial. ZOL significantly reduced skeletal-related events (SREs), and improved progression-free...